This brand name is authorized in Hong Kong SAR China, Japan, Turkey.
The drug LASTET contains one active pharmaceutical ingredient (API):
1
|
UNII
6PLQ3CP4P3 - ETOPOSIDE
|
|
The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA-topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L01CB01 | Etoposide | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CB Podophyllotoxin derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| HK | Department of Health Drug Office | 40663, 40664 |
| JP | 医薬品医療機器総合機構 | 4240001M1067, 4240001M2063, 4240403A2042 |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699650151211, 8699650151228, 8699650151235, 8699650751244 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.